| Literature DB >> 26582242 |
Qingguo Li1,2, Lei Liang1,2, Lu Gan1,3, Guoxiang Cai1,2, Xinxiang Li1,2, Sanjun Cai1,2.
Abstract
Lymph node (LN) status after surgery for rectal cancer is affected by preoperative radiotherapy. The purpose of this study was to perform a population-based evaluation of the impact of pathologic LN status after neoadjuvant radiotherapy on survival. A total of 1,650 patients receiving neoadjuvant chemotherapy in Surveillance, Epidemiology, and End Results Program (SEER)-registered ypIII stage rectal cancer was analyzed. We identified the optimal cutoff for retrieved LNs as 10 (χ2 = 14.006, P < 0.001), which was validated as an independent prognosis factors in a Cox regression model. Further analysis showed that the LN count was only a prognosis factor with the number from 8 to 16(except for 13).After the number 16, the 5-year survival rate decreased gradually. Collectively, our results confirmed that the number of LNs in yp III stage rectal patients was a prognosis factor only with the numbers from 8 to 16(except for 13). Using the total mesorectal excision technique with an adequate pathologic examination, a large number of LNs retrieved (≥17) might indicate worse tumor response grade and poorer survival.Entities:
Mesh:
Year: 2015 PMID: 26582242 PMCID: PMC4652213 DOI: 10.1038/srep16990
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of patients included in the study and make comparison between the ypN1 and ypN2 groups.
| Characteristic | Total | ypN1 | ypN2 | P value |
|---|---|---|---|---|
| (n = 1650) (%) | (n = 1125) (%) | (n = 525) | ||
| Media foullow up(mo) | 64(2–155) | 69 (2–155) | 54(2–153) | <0.001 |
| Sex | 0.412 | |||
| male | 1042 | 718(63.8) | 324(61.7) | |
| female | 608 | 407(36.2.) | 201 (38.3) | |
| Age | 57(20–80) | 58(20-80) | 56(21–80) | 0.059 |
| Race | 0.725 | |||
| White | 1345 | 921(81.9) | 424(80.9) | |
| Black | 128 | 88(7.8) | 40(7.6) | |
| Other | 177 | 116(10.3) | 61(11.6) | |
| Pathological grading | <0.001 | |||
| High/Moderate | 1133 | 808(71.8) | 325(61.9) | |
| Poor/Anaplastic | 376 | 216(19.2) | 160(30.5) | |
| Unknown | 141 | 101(9.0) | 40(7.6) | |
| Histotype | <0.001 | |||
| Adenocarcinoma | 1333 | 955(85.0) | 378(72.3) | |
| Mucinous /Signet ring cell | 313 | 168(15.0) | 145(27.7) | |
| T stage | <0.001 | |||
| Tis | 5 | 4(0.4) | 1(0.2) | |
| T1/T2 | 228 | 182(16.2) | 46(8.8) | |
| T3/4 | 1393 | 920(81.9) | 473(90.1) | |
| TX | 23 | 18(1.6) | 5(1.0) | |
| No. of LNs dissected | 12(1–69) | 10(1–58) | 15(4–69) | <0.001 |
Figure 1X-tile analysis of survival data from the SEER registry.
X-tile analysis was performed using patient data, which were equally divided into training and validation sets, from the SEER registry. X-tile plots of the training sets are shown in the left panels, with plots of matched validation sets shown in the smaller inset. The optimal cut-point highlighted by the black circle in the left panels is shown on a histogram of the entire cohort (middle panels), and a Kaplan-Meier plot (right panels). P values were determined using the cutoff point defined in the training set and applying it to the validation set. Figure 1 shows the optimal cutoff point for the ypN (+) patients (10, χ2 = 14.006, P < 0.001).
Univariate analysis of the influence of different total lymph node count on RCSS in ypIII stage rectal cancer patients.
| Total lymph node count | No. | 5-year CCS | Log-rank χ2 | P value |
|---|---|---|---|---|
| <5 | 250 | 58.3% | 0.810 | 0.368 |
| ≥5 | 1400 | 61.4% | ||
| <6 | 359 | 56.1% | 3.871 | 0.049 |
| ≥6 | 1291 | 62.3% | ||
| <7 | 457 | 57.8% | 2.008 | 0.157 |
| ≥7 | 1193 | 62.1% | ||
| <8 | 593 | 55.9% | 9.609 | 0.002 |
| ≥8 | 1057 | 63.7% | ||
| <9 | 703 | 56.6% | 11.164 | 0.001 |
| ≥9 | 947 | 64.1% | ||
| <10 | 788 | 56.6% | 14.006 | <0.001 |
| ≥10 | 862 | 64.8% | ||
| <11 | 902 | 57.0% | 13.492 | 0.001 |
| ≥11 | 748 | 65.7% | ||
| <12 | 991 | 58.0% | 8.515 | 0.004 |
| ≥12 | 659 | 65.4% | ||
| <13 | 1071 | 59.3% | 3.474 | 0.062 |
| ≥13 | 579 | 64.0% | ||
| <14 | 1140 | 59.4% | 4.127 | 0.042 |
| ≥14 | 510 | 64.3% | ||
| <15 | 1192 | 59.2% | 4.771 | 0.029 |
| ≥15 | 458 | 65.3% | ||
| <16 | 1251 | 59.8% | 3.581 | 0.058 |
| ≥16 | 399 | 64.4% | ||
| <17 | 1304 | 60.4% | 2.165 | 0.141 |
| ≥17 | 346 | 62.3% | ||
| <18 | 1355 | 60.6% | 1.058 | 0.304 |
| ≥18 | 295 | 62.6% | ||
| <19 | 1401 | 60.6% | 1.057 | 0.304 |
| ≥19 | 249 | 62.7% |
*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.
Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing RCSS in ypN(+) rectal cancer patients.
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| 5-year RCCS | Log rank χ2test | P | HR(95%CI) | P | |
| Sex | 0.070 | 0.791 | NI | ||
| Male | 61.1% | ||||
| Female | 60.7% | ||||
| Age | 24.963 | <0.001 | <0.001 | ||
| <60 | 64.6% | Reference | |||
| ≥60 | 55.8% | 1.439(1.247–1.659) | |||
| Race | 6.311 | 0.043 | 0.016 | ||
| Caucasian | 62.1% | Reference | |||
| Black | 51.4% | 1.404(1.095–1.799) | |||
| others | 59.1% | 1.170 (0.931–1.471) | |||
| Grade | 57.252 | <0.001 | <0.001 | ||
| High/ Moderate | 65.3% | Reference | |||
| Poor/ Anaplastic | 44.7% | 1.657(1.412–1.944) | |||
| Unknown | 68.5% | 0.892(0.672–1.184) | |||
| Histotype | 10.876 | 0.001 | 0.462 | ||
| Adenocarcinoma | 62.6% | Reference | |||
| Mucinous/signet ring cell | 54.5% | 1.069(0.895–1.276) | |||
| ypT Stage | 22.284 | <0.001 | 0.003 | ||
| Tis | 60.0% | 1.173(0.287–4.792) | |||
| T1-2 | 76..2% | Reference | |||
| T3-4 | 58.4% | 1.565(1.238–1.979) | |||
| Tx | 60.3% | 1.397(0.722–2.704) | |||
| ypN Stage | 81.663 | <0.001 | <0.001 | ||
| ypN1 | 67.5% | Reference | |||
| ypN2 | 46.7% | 1.638(1.358–1.975) | |||
| N/P LNs ratio | 90.460 | <0.001 | 0.001 | ||
| ≦2.33 | 49.9% | Reference | |||
| >2.33 | 70.6% | 0.735(0.631–0.877) | |||
| No. of LNs | 14.006 | <0.001 | <0.001 | ||
| <10 | 56.6% | Reference | |||
| ≥10 | 64.8% | 0.744(0.631–0.877) | |||
NI: not included in multivariate survival analysis.
N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.
*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.
Figure 2Log-rank tests of rectal cancer cause-specific survival comparing patients with ≥10 lymph nodes with patients who had <10 nodes for (a) stage ypIIIA: χ2 = 0.121, P = 0.728; (b) stage ypIIIB: χ2 = 22.817, P < 0.001; and (c) stage ypIIIC: χ2 = 13.225, P < 0.001.
Univariate and multivariate survival analyses evaluating the number of retrieved LNs influencing RCSS in ypIIIB rectal cancer patients.
| Variable | 5-year RCCS | Univariate analysis | P | Multivariate analysis | |
|---|---|---|---|---|---|
| Log rank χ2test | HR(95% CI) | P | |||
| Sex | 0.576 | 0.448 | NI | ||
| Male | 65.8% | ||||
| Female | 63.8% | ||||
| Age | 19.534 | <0.001 | <0.001 | ||
| <60 | 69.3% | Reference | |||
| ≥60 | 59.5% | 1.500(1.237–1.820) | |||
| Race | 6.580 | 0.037 | 0.025 | ||
| Caucasian | 66.1% | Reference | |||
| Black | 51.8% | 1.556(1.131–2.141) | |||
| others | 67.9% | 1.025(0.731–1.437) | |||
| Grade | 34.685 | <0.001 | <0.001 | ||
| High/ Moderate | 69.1% | Reference | |||
| Poor/ Anaplastic | 47.8% | 1.728(1.388-2.151) | |||
| Unknown | 74.2% | 0.803(0.536–1.203) | |||
| Histotype | 5.186 | 0.023 | 0.325 | ||
| Adenocarcinoma | 66.5% | Reference | |||
| Mucinous/signet ring cell | 58.9% | 1.134(0.883–1.455) | |||
| ypT Stage | 6.475 | 0.039 | 0.009 | ||
| T1-2 | 53.8% | Reference | |||
| T3 | 67.6% | 0.973(0.460-2.059) | |||
| T4 | 60.5% | 1.364(0.625–2.975) | |||
| ypN Stage | 13.788 | <0.001 | 0.002 | ||
| ypN1 | 67.1% | Reference | |||
| ypN2 | 53.6% | 1.616(1.195–2.185) | |||
| N/P LNs ratio | 27.218 | <0.001 | 0.070 | ||
| ≦2.33 | 56.1% | Reference | |||
| >2.33 | 70.4% | 0.801(0.629–1.019) | |||
| No. of LNs | 22.817 | <0.001 | 0.003 | ||
| <10 | 58.8% | Reference | |||
| ≥10 | 72.0% | 0.698(0.552–0.882) | |||
NI: not included in multivariate survival analysis.
N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.
*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.
Univariate and Multivariate survival analyses for evaluating the number of LNs retrieved influencing RCSS in ypIIIC rectal cancer patients.
| Variable | 5-year CCS | Univariate analysis | P | Multivariate analysis | |
|---|---|---|---|---|---|
| Log rank χ2test | HR(95% CI) | P | |||
| Sex | 0.716 | 0.397 | NI | ||
| Male | 40.5% | ||||
| Female | 45.2% | ||||
| Age | 7.615 | 0.006 | 0.010 | ||
| <60 | 45.0% | Reference | |||
| ≥60 | 36.6% | 1.383(1.082–1.769) | |||
| Race | 1.001 | 0.606 | NI | ||
| Caucasian | 42.4% | ||||
| Black | 43.0% | ||||
| others | 37.6% | ||||
| Grade | 9.790 | 0.007 | 0.018 | ||
| High/ Moderate | 45.2% | Reference | |||
| Poor/Anaplastic | 31.4% | 1.470(1.126–1.921) | |||
| Unknown | 50.4% | 1.083(0.709–1.654) | |||
| Histotype | 0.149 | 0.699 | NI | ||
| Adenocarcinoma | 41.5% | ||||
| Mucinous/signet ring cell | 43.2% | ||||
| ypT Stage | 4.371 | 0.037 | 0.033 | ||
| T3 | 50.8% | Reference | |||
| T4 | 39.2% | 1.428(1.030–1.979) | |||
| ypN Stage | 0.648 | 0.421 | NI | ||
| ypN1 | 42.4% | ||||
| ypN2 | 41.7% | ||||
| N/P LNs ratio | 13.621 | <0.001 | <0.001 | ||
| ≦2.33 | 37.3% | Reference | |||
| >2.33 | 56.1% | 0.548(0.394–0.762) | |||
| No. of LNs | 13.225 | <0.001 | 0.013 | ||
| <10 | 32.4% | Reference | |||
| ≥10 | 46.6% | 0.718(0.553–0.933) | |||
NI: not included in multivariate survival analysis.
N/P LNs ratio: The ratio of the number of negative lymph nodes to the number of metastatic lymph nodes.
*P values refer to the log-rank test of the differences between the two survival curves generated using Kaplan-Meier analysis.